Form 4: Korro Bio's Chief Medical Officer, Olukemi Olugemo, Granted Stock Options
SEC Form 4 Filing
Chief Medical Officer of Korro Bio, Olukemi Olugemo, reports the acquisition of stock options and grants a limited power of attorney for SEC filings.
Summary
- Olukemi Olugemo, Chief Medical Officer of Korro Bio, Inc., filed a Form 4 on February 5, 2025, reporting a transaction.
- The transaction involves the acquisition of 42,000 stock options with an exercise price of $33.50 on February 3, 2025.
- These options vest in 48 equal monthly installments starting February 3, 2025, contingent upon continued service.
- Olugemo also granted a limited power of attorney to Ram Aiyar, Vineet Agarwal, Jeffrey Cerio, and Oliver Dolan for SEC filings related to Korro Bio securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The granting of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
- The vesting schedule encourages continued service and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the stock options suggests an expectation of continued service from the Chief Medical Officer.
Industry Context
Stock options are a common form of compensation for executives in the biotechnology industry, aligning their interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, similar to companies like Moderna, BioNTech, and CRISPR Therapeutics.
- The vesting schedule of 48 months is also typical, aligning with industry norms for incentivizing long-term commitment.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer.
- The Chief Medical Officer is incentivized to contribute to the company's success to realize the value of the options.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction: acquisition of stock options and commencement of vesting. |
| 02/03/2025 | Stock options vest in 48 equal monthly installments commencing from this date. |
| 02/02/2035 | Expiration date of the stock options. |
| 02/04/2025 | Date of execution of the Limited Power of Attorney. |
| 02/05/2025 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.